SH2 domains as a target class in cancer and inflammation
Supported by:
12 October 2023
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
About this webinar
SH2 domains are a protein-protein interaction module used in cell signalling. Disrupting protein-protein interactions is an emerging drug discovery modality that is gaining traction. SH2 domains have also been exploited in the development of PROTACs for targeted protein degradation. Eurofins Discovery is now launching a collection of SH2 domain binding assays that utilize the same competitive binding assay principle as our KINOMEscan technology.
Key Takeaways
- Understand how SH2 domains can be used as a drug target to circumvent traditional drug resistance mechanisms
- Explore how SH2 domains can be used as a molecular target for PROTAC and molecular glue discovery
- Discover how the SH2 binding platform from Eurofins Discovery highlights selectivity of small molecules for specific targets in the panel
- Understand how Eurofins Discovery’s E3scan platform can be coupled with our SH2 binding assays to develop novel PROTACs.
Our speaker
Dr Jean Bernatchez, Senior Scientist and San Diego R&D Group Leader, Eurofins Discovery
Jean is a Senior Scientist and the San Diego R&D Group Leader at Eurofins Discovery, and is responsible for developing the company’s portfolio of biochemical assays in the areas of emerging drug targets and targeted protein degradation. Jean has extensive biochemical and cell-based assay development experience across multiple discipline areas in infectious diseases and oncology. Prior to joining Eurofins Discovery, Jean was a postdoctoral scholar at the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, where he developed drug screening assays and conducted high-throughput screening campaigns to identify compounds with activity against Zika virus, SARS-CoV-2, the tropical parasites Trypanosoma cruzi and Leishmania donovani, glioblastoma and meningioma. In over 10 years of work in the drug discovery field, Dr. Bernatchez has published over 30 scientific articles and book chapters in the areas of antivirals, antiparasitics and anticancer agents. He holds a Bachelor of Science degree in Biochemistry (First-Class Honors) and a Doctor of Philosophy degree in Biochemistry (Chemical Biology Interdepartmental Graduate Program), both from McGill University in Montreal, Quebec, Canada.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
